Product Code: 12522
The total size of the molecular quality controls market was USD 191.2 million in 2022, which will reach USD 313.7 million by 2030, propelling at a rate of 6.4% in the years to come, as per a statement by P&S Intelligence.
The independent controls category had the largest share of about 40% in 2022. This is due to the fact that they are produced independently of calibrators, instruments, and reagents, and tests have the supreme sensitivity rate as a result of their tremendously precise, unbiased, and independent valuation of a testing system's or technique's performance.
The single-analyte controls category had a share of over 60%, in 2022, and it will maintain the same in the years to come. This is for the reason that hospitals often use singleplex assays; and with the use of single-analyte, they have benefits for example, easy investigation and understanding and decreased chance of cross-responsiveness, amongst others.
Multi-analyte will witness stable growth rate, about 7%, in the years to come. This can be owing to the progressions in tech and the expansion of new multi-analyte and multi-instrument controls. Clinical labs can save money by the use of these state-of-the-art devices, which integrate frequent instrument-specific controls into a single instrument.
Additionally, by doing away with the necessity for separate quality control actions for each analyte, these controls are responsible for less time consumption.
The diagnostic labs dominated the molecular quality controls market, about 35%, in 2022.
This is due to the fact that the existence of numerous accredited labs in dissimilar regions, which concentrates in services with the use of molecular technology; QC procedures are employed more frequently; regulatory actions are happening more regularly; molecular diagnostics are becoming more expensive; and Alzheimer, diabetes, and cancer cases are increasing, leading to the opening up of numerous labs every year.
North America dominated the industry with about 45%, in 2022. This is because of the high incorporation of leading-edge infra, the enhanced quantity of diagnostic facilities, and the improved count of authorized clinical labs in the region.
Furthermore, the cutting-edge medical facilities in Canada and the U.S., the existence of top manufacturers, and easy access to improved products and techs drive the regional market. In North America, the U.S. has a higher revenue due to large patient population.
Europe follows North America. This is chiefly credited to the snowballing cancer research and related biomarkers and the increasing cancer cases. A study has claimed that there will be a boom in cancer prevalence in Europe, because of the increasing elderly population, as they are prone to long-lasting ailments.
It is because of the increasing count of accredited clinical labs, the demand for molecular quality control will be on the rise in the years to come.
Table of Contents
Chapter 1. Research Scope
- 1.1. Research Objectives
- 1.2. Market Definition
- 1.3. Analysis Period
- 1.4. Market Size Breakdown by Segments
- 1.4.1. Market size breakdown, by product type
- 1.4.2. Market size breakdown, by analyte type
- 1.4.3. Market size breakdown, by application
- 1.4.4. Market size breakdown, by end user
- 1.4.5. Market size breakdown, by region
- 1.4.6. Market size breakdown, by country
- 1.5. Market Data Reporting Unit
- 1.6. Key Stakeholders
Chapter 2. Research Methodology
- 2.1. Secondary Research
- 2.1.1. Paid
- 2.1.2. Unpaid
- 2.1.3. P&S Intelligence database
- 2.2. Primary Research
- 2.3. Market Size Estimation
- 2.4. Data Triangulation
- 2.5. Currency Conversion Rates
- 2.6. Assumptions for the Study
- 2.7. Notes and Caveats
Chapter 3. Executive Summary
Chapter 4. Voice of Industry Experts/KOLs
Chapter 5. Market Indicators
Chapter 6. Industry Outlook
- 6.1. Market Dynamics
- 6.1.1. Trends
- 6.1.2. Drivers
- 6.1.3. Restraints/challenges
- 6.1.4. Impact analysis of drivers/restraints
- 6.2. Impact of COVID-19
- 6.3. Porter's Five Forces Analysis
- 6.3.1. Bargaining power of buyers
- 6.3.2. Bargaining power of suppliers
- 6.3.3. Threat of new entrants
- 6.3.4. Intensity of rivalry
- 6.3.5. Threat of substitutes
Chapter 7. Global Market
- 7.1. Overview
- 7.2. Market Revenue, by Product Type (2017-2030)
- 7.2.1. Instrument-specific controls market revenue, by type (2017-2030)
- 7.3. Market Revenue, by Analyte Type (2017-2030)
- 7.4. Market Revenue, by Application (2017-2030)
- 7.5. Market Revenue, by End User (2017-2030)
- 7.6. Market Revenue, by Region (2017-2030)
Chapter 8. North America Market
- 8.1. Overview
- 8.2. Market Revenue, by Product Type (2017-2030)
- 8.2.1. Instrument-specific controls market revenue, by type (2017-2030)
- 8.3. Market Revenue, by Analyte Type (2017-2030)
- 8.4. Market Revenue, by Application (2017-2030)
- 8.5. Market Revenue, by End User (2017-2030)
- 8.6. Market Revenue, by Country (2017-2030)
Chapter 9. Europe Market
- 9.1. Overview
- 9.2. Market Revenue, by Product Type (2017-2030)
- 9.2.1. Instrument-specific controls market revenue, by type (2017-2030)
- 9.3. Market Revenue, by Analyte Type (2017-2030)
- 9.4. Market Revenue, by Application (2017-2030)
- 9.5. Market Revenue, by End User (2017-2030)
- 9.6. Market Revenue, by Country (2017-2030)
Chapter 10. APAC Market
- 10.1. Overview
- 10.2. Market Revenue, by Product Type (2017-2030)
- 10.2.1. Instrument-specific controls market revenue, by type (2017-2030)
- 10.3. Market Revenue, by Analyte Type (2017-2030)
- 10.4. Market Revenue, by Application (2017-2030)
- 10.5. Market Revenue, by End User (2017-2030)
- 10.6. Market Revenue, by Country (2017-2030)
Chapter 11. LATAM Market
- 11.1. Overview
- 11.2. Market Revenue, by Product Type (2017-2030)
- 11.2.1. Instrument-specific controls market revenue, by type (2017-2030)
- 11.3. Market Revenue, by Analyte Type (2017-2030)
- 11.4. Market Revenue, by Application (2017-2030)
- 11.5. Market Revenue, by End User (2017-2030)
- 11.6. Market Revenue, by Country (2017-2030)
Chapter 12. MEA Market
- 12.1. Overview
- 12.2. Market Revenue, by Product Type (2017-2030)
- 12.2.1. Instrument-specific controls market revenue, by type (2017-2030)
- 12.3. Market Revenue, by Analyte Type (2017-2030)
- 12.4. Market Revenue, by Application (2017-2030)
- 12.5. Market Revenue, by End User (2017-2030)
- 12.6. Market Revenue, by Country (2017-2030)
Chapter 13. U.S. Market
- 13.1. Overview
- 13.2. Market Revenue, by Product Type (2017-2030)
- 13.2.1. Instrument-specific controls market revenue, by type (2017-2030)
- 13.3. Market Revenue, by Analyte Type (2017-2030)
- 13.4. Market Revenue, by Application (2017-2030)
- 13.5. Market Revenue, by End User (2017-2030)
Chapter 14. Canada Market
- 14.1. Overview
- 14.2. Market Revenue, by Product Type (2017-2030)
- 14.2.1. Instrument-specific controls market revenue, by type (2017-2030)
- 14.3. Market Revenue, by Analyte Type (2017-2030)
- 14.4. Market Revenue, by Application (2017-2030)
- 14.5. Market Revenue, by End User (2017-2030)
Chapter 15. Germany Market
- 15.1. Overview
- 15.2. Market Revenue, by Product Type (2017-2030)
- 15.2.1. Instrument-specific controls market revenue, by type (2017-2030)
- 15.3. Market Revenue, by Analyte Type (2017-2030)
- 15.4. Market Revenue, by Application (2017-2030)
- 15.5. Market Revenue, by End User (2017-2030)
Chapter 16. France Market
- 16.1. Overview
- 16.2. Market Revenue, by Product Type (2017-2030)
- 16.2.1. Instrument-specific controls market revenue, by type (2017-2030)
- 16.3. Market Revenue, by Analyte Type (2017-2030)
- 16.4. Market Revenue, by Application (2017-2030)
- 16.5. Market Revenue, by End User (2017-2030)
Chapter 17. U.K. Market
- 17.1. Overview
- 17.2. Market Revenue, by Product Type (2017-2030)
- 17.2.1. Instrument-specific controls market revenue, by type (2017-2030)
- 17.3. Market Revenue, by Analyte Type (2017-2030)
- 17.4. Market Revenue, by Application (2017-2030)
- 17.5. Market Revenue, by End User (2017-2030)
Chapter 18. Italy Market
- 18.1. Overview
- 18.2. Market Revenue, by Product Type (2017-2030)
- 18.2.1. Instrument-specific controls market revenue, by type (2017-2030)
- 18.3. Market Revenue, by Analyte Type (2017-2030)
- 18.4. Market Revenue, by Application (2017-2030)
- 18.5. Market Revenue, by End User (2017-2030)
Chapter 19. Spain Market
- 19.1. Overview
- 19.2. Market Revenue, by Product Type (2017-2030)
- 19.2.1. Instrument-specific controls market revenue, by type (2017-2030)
- 19.3. Market Revenue, by Analyte Type (2017-2030)
- 19.4. Market Revenue, by Application (2017-2030)
- 19.5. Market Revenue, by End User (2017-2030)
Chapter 20. Japan Market
- 20.1. Overview
- 20.2. Market Revenue, by Product Type (2017-2030)
- 20.2.1. Instrument-specific controls market revenue, by type (2017-2030)
- 20.3. Market Revenue, by Analyte Type (2017-2030)
- 20.4. Market Revenue, by Application (2017-2030)
- 20.5. Market Revenue, by End User (2017-2030)
Chapter 21. China Market
- 21.1. Overview
- 21.2. Market Revenue, by Product Type (2017-2030)
- 21.2.1. Instrument-specific controls market revenue, by type (2017-2030)
- 21.3. Market Revenue, by Analyte Type (2017-2030)
- 21.4. Market Revenue, by Application (2017-2030)
- 21.5. Market Revenue, by End User (2017-2030)
Chapter 22. India Market
- 22.1. Overview
- 22.2. Market Revenue, by Product Type (2017-2030)
- 22.2.1. Instrument-specific controls market revenue, by type (2017-2030)
- 22.3. Market Revenue, by Analyte Type (2017-2030)
- 22.4. Market Revenue, by Application (2017-2030)
- 22.5. Market Revenue, by End User (2017-2030)
Chapter 23. Australia Market
- 23.1. Overview
- 23.2. Market Revenue, by Product Type (2017-2030)
- 23.2.1. Instrument-specific controls market revenue, by type (2017-2030)
- 23.3. Market Revenue, by Analyte Type (2017-2030)
- 23.4. Market Revenue, by Application (2017-2030)
- 23.5. Market Revenue, by End User (2017-2030)
Chapter 24. South Korea Market
- 24.1. Overview
- 24.2. Market Revenue, by Product Type (2017-2030)
- 24.2.1. Instrument-specific controls market revenue, by type (2017-2030)
- 24.3. Market Revenue, by Analyte Type (2017-2030)
- 24.4. Market Revenue, by Application (2017-2030)
- 24.5. Market Revenue, by End User (2017-2030)
Chapter 25. Brazil Market
- 25.1. Overview
- 25.2. Market Revenue, by Product Type (2017-2030)
- 25.2.1. Instrument-specific controls market revenue, by type (2017-2030)
- 25.3. Market Revenue, by Analyte Type (2017-2030)
- 25.4. Market Revenue, by Application (2017-2030)
- 25.5. Market Revenue, by End User (2017-2030)
Chapter 26. Mexico Market
- 26.1. Overview
- 26.2. Market Revenue, by Product Type (2017-2030)
- 26.2.1. Instrument-specific controls market revenue, by type (2017-2030)
- 26.3. Market Revenue, by Analyte Type (2017-2030)
- 26.4. Market Revenue, by Application (2017-2030)
- 26.5. Market Revenue, by End User (2017-2030)
Chapter 27. Saudi Arabia Market
- 27.1. Overview
- 27.2. Market Revenue, by Product Type (2017-2030)
- 27.2.1. Instrument-specific controls market revenue, by type (2017-2030)
- 27.3. Market Revenue, by Analyte Type (2017-2030)
- 27.4. Market Revenue, by Application (2017-2030)
- 27.5. Market Revenue, by End User (2017-2030)
Chapter 28. South Africa Market
- 28.1. Overview
- 28.2. Market Revenue, by Product Type (2017-2030)
- 28.2.1. Instrument-specific controls market revenue, by type (2017-2030)
- 28.3. Market Revenue, by Analyte Type (2017-2030)
- 28.4. Market Revenue, by Application (2017-2030)
- 28.5. Market Revenue, by End User (2017-2030)
Chapter 29. U.A.E. Market
- 29.1. Overview
- 29.2. Market Revenue, by Product Type (2017-2030)
- 29.2.1. Instrument-specific controls market revenue, by type (2017-2030)
- 29.3. Market Revenue, by Analyte Type (2017-2030)
- 29.4. Market Revenue, by Application (2017-2030)
- 29.5. Market Revenue, by End User (2017-2030)
Chapter 30. Competitive Landscape
- 30.1. List of Market Players and their Offerings
- 30.2. Competitive Benchmarking of Key Players
- 30.3. Product Benchmarking of Key Players
- 30.4. Recent Strategic Developments
Chapter 31. Company Profiles
- 31.1. LGC Limited
- 31.1.1. Business overview
- 31.1.2. Product and service offerings
- 31.2. Thermo Fisher Scientific Inc.
- 31.2.1. Business overview
- 31.2.2. Product and service offerings
- 31.2.3. Key financial summary
- 31.3. Bio-Rad Laboratories Inc.
- 31.3.1. Business overview
- 31.3.2. Product and service offerings
- 31.3.3. Key financial summary
- 31.4. F. Hoffmann-La Roche Ltd.
- 31.4.1. Business overview
- 31.4.2. Product and service offerings
- 31.4.3. Key financial summary
- 31.5. ZeptoMetrix LLC
- 31.5.1. Business overview
- 31.5.2. Product and service offerings
- 31.6. Quidel Corporation
- 31.6.1. Business overview
- 31.6.2. Product and service offerings
- 31.6.3. Key financial summary
- 31.7. Maine Molecular Quality Controls Inc.
- 31.7.1. Business overview
- 31.7.2. Product and service offerings
- 31.8. Microbiologics Inc.
- 31.8.1. Business overview
- 31.8.2. Product and service offerings
- 31.9. Bio-Techne Corporation
- 31.9.1. Business overview
- 31.9.2. Product and service offerings
- 31.9.3. Key financial summary
- 31.10. Qnostics Ltd.
- 31.10.1. Business overview
- 31.10.2. Product and service offerings
- 31.11. Fortress Diagnostics
- 31.11.1. Business overview
- 31.11.2. Product and service offerings
- 31.12. LGC Clinical Diagnostics Inc.
- 31.12.1. Business overview
- 31.12.2. Product and service offerings
- 31.13. Microbix Biosystems Inc.
- 31.13.1. Business overview
- 31.13.2. Product and service offerings
- 31.13.3. Key financial summary
- 31.14. bioMerieux SA
- 31.14.1. Business overview
- 31.14.2. Product and service offerings
- 31.14.3. Key financial summary
- 31.15. Anchor Molecular
- 31.15.1. Business overview
- 31.15.2. Product and service offerings
Chapter 32. Appendix
- 32.1. Abbreviations
- 32.2. Sources and References
- 32.3. Related Reports